Rapsinski Lab
@raplab.bsky.social
Study ventilator-associated infections and Pseudomonas aeruginosa evolution in the airway of ventilated patients.
We use whole genome sequencing, experimental evolution, clinical samples, and in vitro airway epithelial cell models.
We use whole genome sequencing, experimental evolution, clinical samples, and in vitro airway epithelial cell models.
Thrilled to announce the @raplab.bsky.social is officially NIH K08 Funded!
August 6, 2025 at 8:49 PM
Thrilled to announce the @raplab.bsky.social is officially NIH K08 Funded!
Thrilled to have new people helping in the lab. Welcome @jscioli.bsky.social.!!
March 12, 2025 at 2:29 PM
Thrilled to have new people helping in the lab. Welcome @jscioli.bsky.social.!!
Paper looking at how Avycaz (ceftazidime-avibactam) can select for cross resistance to other beta-lactam/beta-lactamase inhibitor combinations. @aleciarokes.bsky.social @vscooper.micropopbio.org @dariavantyne.bsky.social
Strong start to our P. aeruginosa research!
journals.asm.org/doi/10.1128/...
Strong start to our P. aeruginosa research!
journals.asm.org/doi/10.1128/...
Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa | Microbiology Spectrum
Antibiotic resistance is a significant challenge for physicians trying to treat infections. The development of novel antibiotics to treat resistant infections has not been prioritized for decades, limiting treatment options for infections caused by many ...
journals.asm.org
February 11, 2025 at 6:07 PM
Paper looking at how Avycaz (ceftazidime-avibactam) can select for cross resistance to other beta-lactam/beta-lactamase inhibitor combinations. @aleciarokes.bsky.social @vscooper.micropopbio.org @dariavantyne.bsky.social
Strong start to our P. aeruginosa research!
journals.asm.org/doi/10.1128/...
Strong start to our P. aeruginosa research!
journals.asm.org/doi/10.1128/...
Reposted by Rapsinski Lab
How does avi-caz treatment lead to broad-spectrum treatment failure? Our awesome Peds ID faculty and labbie @rapskiid.bsky.social shows how, by longitudinal sequencing, genotyping, and phenotyping. Congrats Glenn! @dariavantyne.bsky.social @aleciarokes.bsky.social
journals.asm.org/doi/10.1128/...
journals.asm.org/doi/10.1128/...
Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa | Microbiology Spectrum
Antibiotic resistance is a significant challenge for physicians trying to treat infections.
The development of novel antibiotics to treat resistant infections has not been prioritized
for decades, lim...
journals.asm.org
February 11, 2025 at 3:59 PM
How does avi-caz treatment lead to broad-spectrum treatment failure? Our awesome Peds ID faculty and labbie @rapskiid.bsky.social shows how, by longitudinal sequencing, genotyping, and phenotyping. Congrats Glenn! @dariavantyne.bsky.social @aleciarokes.bsky.social
journals.asm.org/doi/10.1128/...
journals.asm.org/doi/10.1128/...
Reposted by Rapsinski Lab
Many people, including academics, don't understand what F&A is for. Please share to help.
1) Translate to "overhead" in common business accounting:
60% IDC => 60/160 = 37.5% overhead (low!)
2) Infographic explaining what it's for, linked here:
www.cogr.edu/sites/defaul...
1) Translate to "overhead" in common business accounting:
60% IDC => 60/160 = 37.5% overhead (low!)
2) Infographic explaining what it's for, linked here:
www.cogr.edu/sites/defaul...
February 10, 2025 at 4:39 PM
Many people, including academics, don't understand what F&A is for. Please share to help.
1) Translate to "overhead" in common business accounting:
60% IDC => 60/160 = 37.5% overhead (low!)
2) Infographic explaining what it's for, linked here:
www.cogr.edu/sites/defaul...
1) Translate to "overhead" in common business accounting:
60% IDC => 60/160 = 37.5% overhead (low!)
2) Infographic explaining what it's for, linked here:
www.cogr.edu/sites/defaul...